Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma

Cameron Gofton; Meera Agar; Jacob George

doi:10.1055/a-1946-5592

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2022; 42(04): 514-530
DOI: 10.1055/a-1946-5592

Review Article

Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma

Authors

Cameron Gofton

¹Department of Gastroenterology and Hepatology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

²Storr Liver Centre, Westmead Hospital, Westmead, New South Wales, Australia
Meera Agar

³Department of Palliative Care, University of Technology Sydney, New South Wales, Australia
Jacob George

²Storr Liver Centre, Westmead Hospital, Westmead, New South Wales, Australia

⁴Department of Medicine, University of Sydney, Camperdown and Darlington Campus, Camperdown, New South Wales, Australia

Abstract

Early palliative and supportive care referral is the standard of care for many malignancies. This paradigm results in improvements in patients' symptoms and quality of life and decreases the costs of medical care and unnecessary procedures. Leading oncology guidelines have recommended the integration of early referral to palliative and supportive services to care pathways for advanced malignancies. Currently, early referral to palliative care within the hepatocellular carcinoma (HCC) population is not utilized, with gastroenterology guidelines recommending referral of patients with Barcelona Clinic Liver Cancer stage D to these services. This review addresses this topic through analysis of the existing data within the oncology field as well as literature surrounding palliative care intervention in HCC. Early palliative and supportive care in HCC and its impact on patients, caregivers, and health services allow clinicians and researchers to identify management options that improve outcomes within existing service provisions.

Keywords

hepatocellular carcinoma - palliative care - palliative and supportive care - implementation

Full Text

References

References
1 McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015; 19 (02) 223-238
2 Rumgay H, Ferlay J, de Martel C. et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer 2022; 161: 108-118
3 Henley SJ, Ward EM, Scott S. et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2020; 126 (10) 2225-2249
4 Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Aust N Z J Public Health 2019; 43 (03) 267-273
5 Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28 (05) 753-770
6 Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380 (15) 1450-1462
7 Gordan JD, Kennedy EB, Abou-Alfa GK. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol 2020; 38 (36) 4317-4345
8 Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ 2005; 330 (7498): 1007-1011
9 Kelley AS, Morrison RS. Palliative care for the seriously ill. N Engl J Med 2015; 373 (08) 747-755
10 Ferrell BR, Chung V, Koczywas M, Smith TJ. Dissemination and implementation of palliative care in oncology. J Clin Oncol 2020; 38 (09) 995-1001
11 Ferrell BR, Temel JS, Temin S. et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2017; 35 (01) 96-112
12 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
13 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
14 Woodrell CD, Hansen L, Schiano TD, Goldstein NE. Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults. Clin Ther 2018; 40 (04) 512-525
15 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma. J Gastroenterol Hepatol 2021; 36 (03) 618-628
16 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 2015; 35 (Suppl. 01) 129-138
17 Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009; 50 (01) 89-99
18 Temel JS, Greer JA, Muzikansky A. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363 (08) 733-742
19 Hoerger M, Greer JA, Jackson VA. et al. Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. J Clin Oncol 2018; 36 (11) 1096-1102
20 Glare PA. Early implementation of palliative care can improve patient outcomes. J Natl Compr Canc Netw 2013; 11 (Suppl. 01) S3-S9
21 Kassianos AP, Ioannou M, Koutsantoni M, Charalambous H. The impact of specialized palliative care on cancer patients' health-related quality of life: a systematic review and meta-analysis. Support Care Cancer 2018; 26 (01) 61-79
22 Von Roenn JH, Voltz R, Serrie A. Barriers and approaches to the successful integration of palliative care and oncology practice. J Natl Compr Canc Netw 2013; 11 (Suppl. 01) S11-S16
23 Giannini EG, Farinati F, Ciccarese F. et al; Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61 (01) 184-190
24 Takayama T, Makuuchi M, Kojiro M. et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol 2008; 15 (04) 972-978
25 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35 (03) 519-524
26 Davis GL, Dempster J, Meler JD. et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc Bayl Univ Med Cent 2008; 21 (03) 266-280
27 Greer JA, Pirl WF, Jackson VA. et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 2012; 30 (04) 394-400
28 Bakitas MA, Tosteson TD, Li Z. et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015; 33 (13) 1438-1445
29 Jordhøy MS, Fayers P, Loge JH, Ahlner-Elmqvist M, Kaasa S. Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 2001; 19 (18) 3884-3894
30 Northouse L, Kershaw T, Mood D, Schafenacker A. Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers. Psychooncology 2005; 14 (06) 478-491
31 Northouse LL, Mood DW, Schafenacker A. et al. Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers. Psychooncology 2013; 22 (03) 555-563
32 Dyar S, Lesperance M, Shannon R, Sloan J, Colon-Otero G. A nurse practitioner directed intervention improves the quality of life of patients with metastatic cancer: results of a randomized pilot study. J Palliat Med 2012; 15 (08) 890-895
33 Wallen GR, Baker K, Stolar M. et al. Palliative care outcomes in surgical oncology patients with advanced malignancies: a mixed methods approach. Qual Life Res 2012; 21 (03) 405-415
34 Farquhar MC, Prevost AT, McCrone P. et al. Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? Findings of a mixed-method randomised controlled trial. BMC Med 2014; 12: 194
35 Bakitas M, Lyons KD, Hegel MT. et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009; 302 (07) 741-749
36 Vanbutsele G, Pardon K, Van Belle S. et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol 2018; 19 (03) 394-404
37 Kayastha N, LeBlanc TW. When to integrate palliative care in the trajectory of cancer care. Curr Treat Options Oncol 2020; 21 (05) 41
38 Kamal AH, Bull JH, Swetz KM, Wolf SP, Shanafelt TD, Myers ER. Future of the palliative care workforce: preview to an impending crisis. Am J Med 2017; 130 (02) 113-114
39 Lupu D, Quigley L, Mehfoud N, Salsberg ES. The growing demand for hospice and palliative medicine physicians: will the supply keep up?. J Pain Symptom Manage 2018; 55 (04) 1216-1223
40 Calton BA, Alvarez-Perez A, Portman DG, Ramchandran KJ, Sugalski J, Rabow MW. The current state of palliative care for patients cared for at leading US cancer centers: the 2015 NCCN Palliative Care Survey. J Natl Compr Canc Netw 2016; 14 (07) 859-866
41 Wichmann AB, Adang EM, Stalmeier PF. et al; PACE. The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: mapping the debate through an integrative review. Palliat Med 2017; 31 (04) 306-322
42 Jordan K, Aapro M, Kaasa S. et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 2018; 29 (01) 36-43
43 Diouf M, Filleron T, Barbare JC. et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013; 58 (03) 509-521
44 Li L, Mo FK, Chan SL. et al. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. BMC Cancer 2017; 17 (01) 8
45 Sternby Eilard M, Hagström H, Mortensen KE. et al. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int 2018; 38 (05) 885-894
46 Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg 2016; 2016: 6120143
47 Chie WC, Yu F, Li M. et al. Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Qual Life Res 2015; 24 (10) 2499-2506
48 Das A, Gabr A, O'Brian DP. et al. Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for hepatocellular carcinoma. J Vasc Interv Radiol 2019; 30 (12) 1924-1933.e2
49 Grumme J, Werncke T, Meine TC. et al. Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. Abdom Radiol (NY) 2020; 45 (10) 3326-3336
50 Hinrichs JB, Hasdemir DB, Nordlohne M. et al. Health-related quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol 2017; 40 (10) 1559-1566
51 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers (Basel) 2019; 11 (06) E841
52 Mikoshiba N, Miyashita M, Sakai T, Tateishi R, Koike K. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life. Psychooncology 2013; 22 (10) 2347-2353
53 Mise Y, Satou S, Ishizawa T. et al. Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg 2014; 38 (04) 958-967
54 Muzellec L, Bourien H, Edeline J. Patients' experience of systemic treatment of hepatocellular carcinoma: a review of the impact on quality of life. Cancers (Basel) 2021; 14 (01) 179
55 Pereira H, Bouattour M, Dioguardi Burgio M. et al; SARAH Trial Group. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer 2021; 154: 46-56
56 Ryoo BY, Merle P, Kulkarni AS. et al. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer 2021; 127 (06) 865-874
57 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1
58 Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol 2012; 21 (01) e23-e30
59 Wehling C, Hornuss D, Schneider P. et al. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2019; 145 (11) 2761-2769
60 Xing M, Webber G, Prajapati HJ. et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study. J Gastroenterol Hepatol 2015; 30 (07) 1167-1174
61 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010; 8 (07) 559-64.e1-10
62 Firkins JL, Tarter R, Driessnack M, Hansen L. A closer look at quality of life in the hepatocellular carcinoma literature. Qual Life Res 2021; 30 (06) 1525-1535
63 Guo YM. Effects of emotional intervention and Chinese medicated diet in improving the quality of life in patients with liver cancer after chemotherapy. Chin J Clin Rehabil 2005; 9: 30-31
64 Lin ML, Tsang YM, Hwang SL. Efficacy of a stress management program for patients with hepatocellular carcinoma receiving transcatheter arterial embolization. J Formos Med Assoc 1998; 97 (02) 113-117
65 Steel JL, Nadeau K, Olek M, Carr BI. Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma. J Psychosoc Oncol 2007; 25 (03) 19-42
66 Bianchi G, Loguercio C, Sgarbi D. et al. Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis 2003; 35 (01) 46-54
67 Kondo Y, Yoshida H, Tateishi R. et al. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22 (02) 197-203
68 Steel JL, Chopra K, Olek MC, Carr BI. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res 2007; 16 (02) 203-215
69 Chen JJ, Huang SS, Li IF, Lin KP, Tsay SL. Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. Support Care Cancer 2019; 27 (12) 4665-4674
70 Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF. Symptom distress in patients with hepatocellular carcinoma toward the end of life. Oncol Nurs Forum 2017; 44 (06) 665-673
71 Kaiser K, Mallick R, Butt Z, Mulcahy MF, Benson AB, Cella D. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Support Care Cancer 2014; 22 (04) 919-926
72 Veloso VI, Tripodoro VA. Caregivers burden in palliative care patients: a problem to tackle. Curr Opin Support Palliat Care 2016; 10 (04) 330-335
73 Stajduhar KI. Examining the perspectives of family members involved in the delivery of palliative care at home. J Palliat Care 2003; 19 (01) 27-35
74 McDonald J, Swami N, Hannon B. et al. Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial. Ann Oncol 2017; 28 (01) 163-168
75 Lütscher J, Siegenthaler CH, Hertler C. et al. Retrospective analysis of emotional burden and the need for support of patients and their informal caregivers after palliative radiation treatment for brain metastases. Curr Oncol 2022; 29 (06) 4235-4244
76 Lee JE, Shin DW, Cho J. et al. Caregiver burden, patients' self-perceived burden, and preference for palliative care among cancer patients and caregivers. Psychooncology 2015; 24 (11) 1545-1551
77 Kissane DW, McKenzie M, McKenzie DP, Forbes A, O'Neill I, Bloch S. Psychosocial morbidity associated with patterns of family functioning in palliative care: baseline data from the Family Focused Grief Therapy controlled trial. Palliat Med 2003; 17 (06) 527-537
78 Kim SH, Hwang IC, Ko KD. et al. Association between the emotional status of family caregivers and length of stay in a palliative care unit: a retrospective study. Palliat Support Care 2015; 13 (06) 1695-1700
79 Holm M, Goliath I, Södlind H, Alvariza A. Leading an intervention for family caregivers-a part of nursing in palliative care. Int J Palliat Nurs 2017; 23 (04) 166-172
80 Hannon B, Swami N, Rodin G, Pope A, Zimmermann C. Experiences of patients and caregivers with early palliative care: a qualitative study. Palliat Med 2017; 31 (01) 72-81
81 Woodrell CD, Mitra A, Hamilton A, Hansen L. Burden, quality of life, and palliative care for family caregivers of individuals with advanced liver disease: a systematic literature review. Curr Hepatol Rep 2021; 20 (04) 198-212
82 Steel JL, Geller DA, Carr BI. Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. Qual Life Res 2005; 14 (04) 1025-1033
83 Liu XY, Shen J, Ye ZX. et al. Congruence in symptom assessment between hepatocellular carcinoma patients and their primary family caregivers in China. Support Care Cancer 2013; 21 (10) 2655-2662
84 Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep 2018; 8 (01) 2861
85 Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ 2018; 361: k1415
86 Hansen L, Rosenkranz SJ, Wherity K, Sasaki A. Living with hepatocellular carcinoma near the end of life: family caregivers' perspectives. Oncol Nurs Forum 2017; 44 (05) 562-570
87 Wakefield D, Bayly J, Selman LE, Firth AM, Higginson IJ, Murtagh FE. Patient empowerment, what does it mean for adults in the advanced stages of a life-limiting illness: a systematic review using critical interpretive synthesis. Palliat Med 2018; 32 (08) 1288-1304
88 Alterio RE, Ju MR, Wang SC, Mansour JC, Yopp A, Porembka MR. Socioeconomic and racial/ethnic disparities in receipt of palliative care among patients with metastatic hepatocellular carcinoma. J Surg Oncol 2021; 124 (08) 1365-1372
89 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
90 Yopp AC, Mansour JC, Beg MS. et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014; 21 (04) 1287-1295
91 Rogal SS, Hansen L, Patel A. et al. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. Hepatology 2022; 76 (03) 819-853
92 Bonnichsen M, Liu K, Powter E, Majumdar A, Strasser SI, McCaughan G. Palliative care referrals for advanced stage hepatocellular carcinoma. J Gastroenterol Hepatol 2019; 34: 91-92
93 Zou WY, El-Serag HB, Sada YH. et al. Determinants and outcomes of hospice utilization among patients with advance-staged hepatocellular carcinoma in a Veteran Affairs population. Dig Dis Sci 2018; 63 (05) 1173-1181
94 Adair T. Who dies where? Estimating the percentage of deaths that occur at home. BMJ Glob Health 2021; 6 (09) e006766
95 Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice utilization and its effect on acute care needs at the end of life in medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract 2017; 13 (03) e197-e206
96 Virdun C, Luckett T, Lorenz KA, Phillips J. National quality indicators and policies from 15 countries leading in adult end-of-life care: a systematic environmental scan. BMJ Support Palliat Care 2018; 8 (02) 145-154
97 Fricker ZP, Serper M. Current knowledge, barriers to implementation, and future directions in palliative care for end-stage liver disease. Liver Transpl 2019; 25 (05) 787-796
98 Kelly SG, Campbell TC, Hillman L, Said A, Lucey MR, Agarwal PD. The utilization of palliative care services in patients with cirrhosis who have been denied liver transplantation: a single center retrospective review. Ann Hepatol 2017; 16 (03) 395-401
99 Lamba S, Murphy P, McVicker S, Harris Smith J, Mosenthal AC. Changing end-of-life care practice for liver transplant service patients: structured palliative care intervention in the surgical intensive care unit. J Pain Symptom Manage 2012; 44 (04) 508-519
100 Patel AA, Woodrell C, Ufere NN. et al; Palliative Care Education, Advocacy, and Research in Liver Disease (PEARL) Workgroup and the AASLD Public Health / Healthcare Delivery Special Interest Group (SIG). Developing priorities for palliative care research in advanced liver disease: a multidisciplinary approach. Hepatol Commun 2021; 5 (09) 1469-1480
101 Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med 2014; 17 (11) 1271-1277
102 Rakoski MO, Volk ML. Palliative care and end-stage liver disease: a critical review of current knowledge. Curr Opin Gastroenterol 2019; 35 (03) 155-160
103 Shinall Jr MC, Bonnet K, Schlundt D, Verma M. Integrating specialist palliative care in the liver transplantation evaluation process: a qualitative analysis of hepatologist and palliative care provider views. Liver Transpl 2022; 28 (04) 678-688
104 Walling AM, Schreibeis-Baum H, Pimstone N. et al. Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med 2015; 18 (04) 378-381
105 Hwang S-J, Chang HT, Hwang IH, Wu CY, Yang WH, Li CP. Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study. J Palliat Med 2013; 16 (07) 780-785
106 Chiang J-K, Kao YH. The impact of hospice care on survival and cost saving among patients with liver cancer: a national longitudinal population-based study in Taiwan. Support Care Cancer 2015; 23 (04) 1049-1055
107 Kao YH, Chiang JK. Effect of hospice care on quality indicators of end-of-life care among patients with liver cancer: a national longitudinal population-based study in Taiwan 2000-2011. BMC Palliat Care 2015; 14: 39
108 Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol 2017; 15 (10) 1612-1619.e4
109 Riolfi M, Buja A, Zanardo C, Marangon CF, Manno P, Baldo V. Effectiveness of palliative home-care services in reducing hospital admissions and determinants of hospitalization for terminally ill patients followed up by a palliative home-care team: a retrospective cohort study. Palliat Med 2014; 28 (05) 403-411
110 Baumann AJ, Wheeler DS, James M, Turner R, Siegel A, Navarro VJ. Benefit of early palliative care intervention in end-stage liver disease patients awaiting liver transplantation. J Pain Symptom Manage 2015; 50 (06) 882-6.e2
111 Woodrell CD, Goldstein NE, Moreno JR, Schiano TD, Schwartz ME, Garrido MM. Inpatient specialty-level palliative care is delivered late in the course of hepatocellular carcinoma and associated with lower hazard of hospital readmission. J Pain Symptom Manage 2021; 61 (05) 940-947.e3
112 de Avila V, Paik JM, de Avila L. et al. Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. JHEP Rep 2021; 3 (02) 100236
113 Zimmermann C, Swami N, Krzyzanowska M. et al. Perceptions of palliative care among patients with advanced cancer and their caregivers. CMAJ 2016; 188 (10) E217-E227
114 Boyd K, Moine S, Murray SA, Bowman D, Brun N. Should palliative care be rebranded?. BMJ 2019; 364: l881
115 Acuna SA, Lam W, Daly C, Kim SJ, Baxter NN. Cancer evaluation in the assessment of solid organ transplant candidates: a systematic review of clinical practice guidelines. Transplant Rev (Orlando) 2018; 32 (01) 29-35
116 Mudigonda P, Berardi C, Chetram V, Barac A, Cheng R. Implications of cancer prior to and after heart transplantation. Heart 2022; 108 (06) 414-421
117 Al-Adra DP, Hammel L, Roberts J. et al. Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant 2021; 21 (02) 460-474
118 Tombazzi CR, Howe CF, Slaughter JC, Obstein KL. Rate of and factors associated with palliative care referral among patients declined for liver transplantation. J Palliat Med 2022; 25 (09) 1404-1408
119 Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol 2013; 24 (Suppl. 02) ii15-ii23
120 Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc 2013; 6: 189-195
121 Ufere NN, Donlan J, Waldman L. et al. Physicians' perspectives on palliative care for patients with end-stage liver disease: a national survey study. Liver Transpl 2019; 25 (06) 859-869
122 Ufere NN, Donlan J, Waldman L. et al. Barriers to use of palliative care and advance care planning discussions for patients with end-stage liver disease. Clin Gastroenterol Hepatol 2019; 17 (12) 2592-2599
123 Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG 2018; 125 (13) 1716
124 Magill N, Knight R, McCrone P, Ismail K, Landau S. A scoping review of the problems and solutions associated with contamination in trials of complex interventions in mental health. BMC Med Res Methodol 2019; 19 (01) 4
125 DeCamp M, Alasmar A, Fischer S, Kutner JS. Meeting ethical challenges with authenticity when engaging patients and families in end-of-life and palliative care research: a qualitative study. BMC Palliat Care 2022; 21 (01) 74
126 Grande GE, Todd CJ. Why are trials in palliative care so difficult?. Palliat Med 2000; 14 (01) 69-74
127 Hemming K, Eldridge S, Forbes G, Weijer C, Taljaard M. How to design efficient cluster randomised trials. BMJ 2017; 358: j3064
128 Verma M, Kosinski AS, Volk ML. et al. Introducing palliative care within the treatment of end-stage liver disease: the study protocol of a cluster randomized controlled trial. J Palliat Med 2019; 22 (S1): 34-43
129 Given B, Given CW, McCorkle R. et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 2002; 29 (06) 949-956
130 Rummans TA, Clark MM, Sloan JA. et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006; 24 (04) 635-642
131 Northouse LL, Mood DW, Schafenacker A. et al. Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer 2007; 110 (12) 2809-2818
132 Clark MM, Rummans TA, Atherton PJ. et al. Randomized controlled trial of maintaining quality of life during radiotherapy for advanced cancer. Cancer 2013; 119 (04) 880-887
133 Zimmermann C, Swami N, Krzyzanowska M. et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014; 383 (9930): 1721-1730
134 May P, Garrido MM, Cassel JB. et al. Prospective cohort study of hospital palliative care teams for inpatients with advanced cancer: earlier consultation is associated with larger cost-saving effect. J Clin Oncol 2015; 33 (25) 2745-2752
135 Grudzen CR, Richardson LD, Johnson PN. et al. Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial. JAMA Oncol 2016; 2 (05) 591-598
136 Steel JL, Geller DA, Kim KH. et al. Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. Cancer 2016; 122 (08) 1270-1282